Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05096715

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Phase IB Study of Atezolizumab and Bevacizumab With SBRT for Unresectable Hepatocellular Carcinoma

Sponsor: Genentech, Inc.

Conditions Unresectable Hepatocellular Carcinoma

Interventions Atezolizumab Bevacizumab Stereotactic body radiation therapy (SBRT)

Updated 4 times since 2021 Last updated: Feb 13, 2026 Started: Aug 23, 2022 Primary completion: Jan 31, 2027 Completion: Jan 31, 2032

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Unresectable Hepatocellular Carcinoma and is currently actively recruiting participants. Genentech, Inc. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
Nov 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States